Teva CEO Richard Francis to present at three major September investor conferences

0 min read | Published on 02 Sept 2026, 02:05 AM |Updated on 02 Sept 2026, 02:05 AM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Teva CEO Richard Francis to present at three investor conferences in September 2026
First appearance at Morgan Stanley conference on September 14, 2026
Subsequent presentations scheduled for J.P. Morgan and BofA conferences
Live webcasts available via Teva Investor Relations website

*this image is generated using AI for illustrative purposes only.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that President and CEO Richard Francis will present at three major investor conferences in September 2026.

The presentations will provide updates on the company's strategy and operations during key industry events.

Conference Schedule

Francis is scheduled to speak at the following events:

Conference	Date	Time (ET)
Morgan Stanley 24th Annual Global Healthcare Conference	September 14, 2026	8:30 am
J.P. Morgan U.S. All Stars Conference	September 22, 2026	3:00 am
BofA Global Healthcare Conference 2026	September 23, 2026	5:55 am

Accessing the Presentations

Investors can access live webcasts of the presentations via Teva’s Investor Relations website. Archived versions will be available within 24 hours after each live discussion concludes.

About Teva

Teva is transforming into a leading innovative biopharmaceutical company, supported by its generics business. The company focuses on neuroscience, immunology, complex generic medicines, biosimilars, and pharmacy brands worldwide.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the strategic updates at these September 2026 conferences influence Teva's valuation multiples in the near term?

What specific progress in Teva's neuroscience or immunology pipeline is likely to be highlighted as a key growth driver?

Could the presentations signal any upcoming changes in Teva's approach to its generics business amid increasing market competition?

Teva commits to lowering select Medicaid drug costs in US deal

0 min read | Published on 01 Sept 2026, 01:58 AM |Updated on 01 Sept 2026, 01:58 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Teva commits to lowering costs for select Medicaid-covered drugs
Deal aligns US pricing with leading developed markets
Includes MFN commitment for future innovative products
Supports domestic manufacturing and API reserves

*this image is generated using AI for illustrative purposes only.

Teva Pharmaceuticals announced a commitment with the Trump Administration to reduce costs for select medicines covered by Medicaid. The agreement aims to expand patient access while supporting investment in scientific innovation and pharmaceutical manufacturing capabilities.

Chris Fox, President of Teva USA, stated that the company shares the Administration’s goal of improving access to affordable medicines. He emphasized Teva’s focus on delivering affordable medicines to Americans while investing in domestic manufacturing.

Deal Structure and Pricing Framework

Teva remains in active discussions to finalize a deal anchored in the President’s drug pricing priorities. If agreed, Teva would align U.S. Medicaid pricing for select medicines with pricing in leading developed markets through the GENEROUS framework.

The proposed agreement includes:

Alignment of U.S. Medicaid pricing for select medicines with leading developed markets
A prospective Most-Favored-Nation (MFN) commitment for applicable future innovative product launches
A dedicated reserve of certain active pharmaceutical ingredients (API) for public health needs
Continued investment into U.S. pharmaceutical manufacturing capabilities

Conditions for reaching a final agreement remain confidential.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might Teva's adoption of the GENEROUS pricing framework influence other generic drug manufacturers to negotiate similar Medicaid agreements?

What impact could the prospective Most-Favored-Nation commitment have on the profitability and launch strategies of Teva's future innovative products in the U.S. market?

Will this agreement serve as a precedent for broader federal drug pricing reforms beyond Medicaid, potentially affecting Medicare or private insurance negotiations?